{"denoms":[{"counts":[{"groupId":"OG000","value":"0"}],"units":"Participants"}],"description":"For OS, participants who remain alive at the end of study follow-up will be censored at the time when the participants is known to be alive. Results will be summarized using the Kaplan-Meier method. The 12-months percentage of participants alive, 25th percentile, median, and 75th percentile, along with corresponding 95% confidence intervals, will be reported.","groups":[{"description":"Participants received pembrolizumab IV over 30 minutes on day 1. Cycles repeat every 21 days for up to 2 years in the absence of disease progression or unacceptable toxicity.","id":"OG000","title":"Treatment (Pembrolizumab)"}],"populationDescription":"Data not collected","reportingStatus":"POSTED","timeFrame":"Up to 2 years","title":"Median Overall Survival (OS) at 12 Months","type":"SECONDARY"}